Idorsia: H1 preview: look through the optics, watch the catalysts

Research evidence excerpt

Idorsia: H1 preview: look through the optics, watch the catalysts

Deutsche Bank

Research

Rating Company Date

Hold Idorsia 19 June 2026

Forecast Change

Europe

Switzerland

Reuters Bloomberg Exchange Ticker Price at 18 Jun 2026 (CHF) 5.85

IDIA.S IDIA SW SWX IDIA

Price Target (CHF) 4.50

Pharmaceuticals

52-week range (CHF) 5.85 - 1.87

H1 preview: look through the optics,

Valuation & Risks watch the catalysts

Henrietta Boeg

Summary takes Research Associate

Following the recent DD move — out of line with both the Swiss market and +44-20-754-10119

European healthcare —we take the opportunity to outline our view on (1) potential

Niall Alexander

key drivers of the move and (2) revisit the investment thesis ahead of Q2 results Research Analyst

(30th July), noting the underlying fundamental story remains unchanged and we +44-20-754-12185

reiterate our HOLD recommendation.

Emmanuel Papadakis, Ph.D., CFA

Research Analyst

Why has the stock moved? +44-20-754-18522

In the absence of fundamental newsflow across the three key catalysts

Shashindra Seresinhe

highlighted in our post-Q1 note (IDIA : Post Q1: Transfer of Coverage (30/04/26)),

Research Associate

we view the recent reaction as largely technical rather than fundamental driven.

Specifically, we note the disclosure (link) of a ~9% holding on the SIX exchange in

April 2026, which appears to have brought renewed market attention to the story, Supun Ukwatta

potentially combined with a delayed positive reaction to the extended cash runway

(now 2028) following CHF 250m secured debt financing announced 9th June.

Kate Farrelly

Near-term catalysts and outlook

n We remind investors that the most prominent potential near-term catalyst

remains US de-scheduling of the DORA class (a process that takes ~6–9

Key changes